Myocardial Infarction: Three drug trials to watch in 2024

With acute coronary syndromes, prompt medical attention is needed to reduce the amount of damage to the heart muscle. There are very limited treatments currently offering medical intervention at such an early stage which some pipeline medications are trying to address.

In April 2023, the therapeutic pipeline consisted of around 140 pharmaceuticals drugs from discovery through to late-stage clinical development, with 36% of drugs in Phase I and above.